[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Editor's Correspondence
September 18, 2006

Infliximab and Human Immunodeficiency Virus Infection: Viral Load Reduction and CD4+ T-Cell Loss Related to Apoptosis

Arch Intern Med. 2006;166(16):1783-1784. doi:10.1001/archinte.166.16.1783

Infliximab is a monoclonal anti–tumor necrosis factor (TNF)-α antibody indicated in steroid-resistant and/or fistulizing Crohn disease (CD). Reactivation of chronic viral hepatitis as well as opportunistic infections have been reported as adverse effects,1,2 but the impact of such drugs on patients' virological and immunological status remains unknown.3